

LETTER FOR PCT ARTICLE 34 AMENDMENT OF DESCRIPTION AND CLAIMS

Date: 2004. 5. 31

Amendment to the description and the claims under Article 34

International Application No.: PCT/KR2003/002034

International Filing Date: October 2, 2003

Applicant: B & C BIOPHARM CO., LTD.

633-2, Goan-ri, Baekam-myeon, Yongin-si, Gyeonggi-do 449-863
Republic of Korea (Tel. 82-31-330-7717)

Agent: LEE, Duck-Rog

YEiLPAT Bldg., 669-17, Yorksam-dong, Kangnam-ku, Seoul 135-915
Republic of Korea (Tel. 82-2-555-1717)

Applicant's or Agent's File reference: YL03002PCT

Dear Sir(s):

Applicant herewith submits replacement sheets number pages 1 to 11 and 13 to 16 to replace sheets number pages 1 to 11 and 13 to 16, originally filed for this application.

In respect of each claim appearing in the international application based on the replacement sheets submitted herewith, and in accordance with PCT section 205, the claims are as following:

(i) amended: claims 1 to 3

Furthermore, in respect of the description appearing in the international application based on the replacement sheets submitted herewith, in accordance with PCT section 205, the description are as following:

(i) page 1:

1. "More particularly, ~ to" phrase is changed into ", and more particularly novel~" on the 7th line.

... Cont'd next page

2. "... (I)" mark is added in the end of formula.
3. "derivatives" is corrected to "derivative" on the 6th to the 7th lines.
4. "2 hundred" is corrected to "200" on the 21st line.

(ii) page 2:

1. "into" is added right after "it is processed" on the 14th line.
2. "3,100" to "3,010" on the 8th line and "flaviviruses" to "Flaviviruses" on the 27th line are corrected respectively.
3. "formation of the virus and RNA replication" to "expression and RNA replication of the virus" on the 12th line and "(NS3) of the virus and cofactor(NS2, NS4A, and NS4B)" phrase to "(NS3) and cofactor(NS2, NS4A, and NS4B) of the virus" on the 21st to the 22nd lines, respectively are changed.
4. "the" on the 9th line, "strand" on the 13th line and "i.e." on the 16th line are deleted respectively.
5. "membrane" to "envelope" on the 6th line, "proliferation" to "replication" on the 19th line and "part" to "role" on the 24th line, respectively are changed.

(iii) page 3:

1. "the" right ahead of "3'-UTR" on the 15th line, "it is reported that" right ahead of "-poly(U)-part" on the 21st line and "the" right ahead of "most" on the 6th line are added respectively.
2. "disclosing translation" on the 8th to the 9th lines to "initiation of translational" and "has" on the 22nd line to "induces" are changed respectively.
3. "when the RNA replication starts" phrase is inserted right ahead of "Reference" on the 26th line.

(iv) page 4:

1. "consists of" is corrected to "is an enzyme consisting of" on the 2nd line.
2. "According to~." paragraph on the 3rd to the 5th lines is deleted.
3. "(RBD)" is inserted right ahead of "i.e." on the 6th line.
4. "back" is deleted on the 17th line.

(v) page 5:

1. "Unfortunately, ~." paragraph on the 10th to the 12th lines is deleted.
2. "is found because of" is changed to "exist as" on the 14th line.
3. "HCV's" on the 23rd line and "(replicase" on the 27th line are deleted respectively.
4. "motif" is changed to "enzyme" on the 27th line.

... Cont'd next page

(vi) page 6:

1. "HCV C relapsed again" phrase is changed to "relapsed into hepatitis C again" on the 17th line.
2. "little" to "low", "anti-virus" to "antiviral", "prepare" to "synthesize" and "formula 1" to "formula I" are changed respectively on the 21st to the 26th lines.
3. "compound" is changed to "small molecule" on the 21st line.

(vii) page 7:

1. "these compounds are" phrase is corrected to "this compound is" on the first line.
2. "~derivatives, which are effective for inhibiting hepatitis C virus(HCV), and pharmaceutically acceptable salts and a method for preparing the compounds" is changed to "~ derivative, which is effective for inhibiting the replication of HCV, ~ salts thereof and ~ compound" on the 6th to the 8th lines.
3. "little" is changed to "low" on the 11th line.
4. "there are provided" is changed to "the present invention provides" on the 12th line.
5. "... (I)" mark is added in the end of formula.
6. "compounds" on the 16th and the 18th line to "compound", "formula 1" on the 13th and the 19th line to "formula I", "derivatives" on the 13th line to "derivative" and "salts" on the 14th line to "salt" are corrected respectively.
7. "are available" is added right after "free acids" on the 18th line.

(viii) page 8:

1. "4-trifluoroacetic acid" on the 3rd line to "trifluoroacetic acid", "derivatives" on the 7th and the 9th line to "derivative", "scheme I" on the 7th and the 9th line to "scheme", "6-Methylepyridine" on the 9th line to "6-Methylpyridine", "formula 2" on the 11th and the 13th line to "formula II", "formula 3" on the 12th and the 14th line to "formula III" and "4-morforino" on the 11th and the 14th line to "4-morpholino" are corrected respectively.
2. "weak ~6 days" paragraph is changed to "the reactions are performed in organic solvents such as methanol, ethanol, isopropanol, dichloromethane, chloroform, acetonitrile; N, N-dimethylformamide, acetone and the like, and in the presence of the weak tertiary organic bases such as pyridine, 2,6-lutidine, 4-dimethylaminopyridine, N,N-dimethylaniline and the like, for a relatively long period of time, namely one day to 6 days at a temperature in the range of 40-80°C" on the 16th to the 21st lines.

... Cont'd next page

(ix) page 9:

1. "formula 1" on the 3rd, 5th, 12th and 21st line to "formula I" and "derivatives" on the 3rd line to "derivative" are corrected respectively.
2. "an" is inserted right ahead of "active ingredient" on the 4th line.
3. "more than one compound" is changed to "the compound" on the 11th line.
4. "or detergent (or surfactant)" is changed to "or surfactant" on the 9th line.

(x) page 10:

1. "Example" on the 4th line to "Example 1", "4-morforino" on the 4th and the 6th line to "4-morpholino" and "mL" on the 7th, 10th and 13th line to "ml" are corrected respectively.
2. ", and heated~" is changed to "The mixture was heated to 60°C and stirred for five days at 60°C." on the 7th to the 8th lines.
3. "solid extracted from the reaction" is changed to "precipitated solid" on the 9th line.
4. "stirred for 1 hour" phrase is changed to "the residue was crystallized with 60 ml of methanol, and stirred for 1 hour" on the 12th line.
5. "any" and "therein" are deleted on the 10th to the 11th lines.
6. "with 60 mL of methanol" phrase is deleted on the 11th to the 12th lines.
7. "Then, the organic layer" to "The product" and "filtered and" to "filtered," are changed respectively on the 12th to the 13th lines.
8. "to give a solid product. The product was" on the 13th to the 14th lines is changed to "and".
9. "(89%)" is corrected to "(80%)" on the 15th line.

(xi) page 11:

1. "with" is corrected to "into" on the 4th line.
2. "with" is inserted right ahead of "the binding" on the 14th line.
3. "i.e." is deleted on the 26th line.

(xii) page 13:

1. "mL" of Table 1 and on the 13th line is corrected to "ml".
2. "above" is inserted right ahead of "table" on the second line.
3. "compounds" on the 2nd and the 14th line to "compound" and "derivatives" on the 10th and the 17th line to "derivative" are corrected respectively.
4. "MTT analysis" on the 12th line to "MTT assay using HepG 2 cell line", "every" on the 12th line to "the" and "they are" on the 14th line to "it is" are changed respectively.

... Cont'd next page

5. "according to the present invention" phrase is inserted right ahead of "represented" on the 17th line.

(xiii) page 16:

1. "More particularly, ~ to" phrase is changed into ", and more particularly novel~" on the 4th to the 5th line.
2. "(I)" of formula is corrected to "... (I)".
3. "derivatives" to "derivative" on the 5th to the 11th lines and "have" to "has" on the 11th line are corrected respectively.
4. "(HCV)" is added right after "virus" on the 12th line.

As mentioned in the above, the description appearing in the international application based on the replacement sheets submitted herewith is amended to correct errors in specification to the extent that it does not change the scope of the subject matter.

Furthermore, in respect of the title of the invention appearing in the international application based on the replacement sheets submitted herewith, in accordance with PCT section 205, the title of the invention "6-METHYLPYRIDINE DERIVATIVES, METHOD FOR PREPARING THEREOF AND ANTIVIRAL PHARMACEUTICAL COMPOSITION COMPRISING THE SAME" is changed to "6-METHYLPYRIDINE DERIVATIVE, METHOD FOR PREPARING THEREOF AND ANTIVIRAL PHARMACEUTICAL COMPOSITION COMPRISING THE SAME".

your sincerely,

LEE, Duck-Rog